TITLE

Predicting ALS Progression

AUTHOR(S)
Rubin, Michael
PUB. DATE
September 2007
SOURCE
Neurology Alert;Sep2007, Vol. 26 Issue 1, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The diagnosis of amyotrophic lateral sclerosis (ALS) is devastating for patient and family alike. Nevertheless, the ability to predict which patients with lower motor neuron disease will progress to full blown ALS would be beneficial by enabling earlier enrollment into clinical trials, offering added hope, and potentially therapeutic benefit. Thirty-three patients, evaluated at the Paris or Strasbourg Motor Neuron Disease Center between 2003 - 2005 for a purely lower motor neuron syndrome, were followed prospectively over 12 months to determine whether progression to ALS could be predicted by positive Nogo-A expression in muscle biopsy. Lower motor neuron involvement was documented clinically by the presence of weak, wasted, fasciculating muscles, and confirmed electrodiagnostically by reduced motor evoked potential amplitudes on nerve conduction studies, or spontaneous activity (positive sharp waves and fibrillation potentials), or a reduced interference pattern on needle electromyography. At entry, no patient demonstrated upper motor neuron signs (spasticity, hyperreflexia, retained reflexes in weak wasted muscles, Hoffman or Babinski signs, loss of superficial abdominal reflexes), bulbar involvement, respiratory compromise, or sensory signs. All underwent spinal magnetic resonance imaging, sedimentation rate, serum immunoelectrophoresis and immunofixation, anti-GM1 and anti-poliovirus antibodies, and thyroid and parathyroid function. Muscle biopsy, usually of the deltoid (n = 28) unless it was deemed too atrophic, was performed as part of the routine workup, and Nogo-A expression was measured by Western blot techniques. Neurologists blinded to Nogo-A test results performed quarterly neurologic examinations to determine disease progression. Strikingly, among 17 patients who tested positive for Nogo-A on muscle biopsy, found as early as 3 months following onset, 15 progressed to a definite ALS diagnosis, yielding 91% accuracy, 94% sensitivity, and 88% specificity. Among 16 Nogo-A negative patients, only 1 progressed to ALS over a mean followup of 25 months (14-37 months). Final diagnoses in this group included progressive spinal muscular atrophy (n = 6), lumbosacral root compression (n = 4), postpolio syndrome (n = 2), and one each of chronic inflammatory demyelinating polyneuropathy, idiopathic brachial plexopathy, and SMN1-linked spinal muscular atrophy. The authors conclude that muscle Nogo-A expression may accurately and specifically predict progression of lower motor neuron disease to ALS.
ACCESSION #
26651070

 

Related Articles

  • Electrodiagnostic Evaluation of Motor Neuron Disorders. Shipe, Carol; Zivkovic, Saša A. // American Journal of Electroneurodiagnostic Technology;Mar2004, Vol. 44 Issue 1, p30 

    Amyotrophic lateral sclerosis (ALS) is the most common adult motor neuron disorder and leads usually to death within two to five years after diagnosis. Clinically, ALS presents with fasciculations, progressive weakness, muscle atrophy, and spasticity. It is a clinical diagnosis, supported by...

  • Detecting fasciculations in amyotrophic lateral sclerosis: duration of observation required. Mills, Kerry R. // Journal of Neurology, Neurosurgery & Psychiatry;May2011, Vol. 82 Issue 5, p549 

    A practical issue in the diagnosis of amyotrophic lateral sclerosis (ALS) is how long the EMG must be observed before a muscle can be declared free of fasciculations with some degree of certainty. To answer this question, the intervals between fasciculation potentials (FPs) were recorded from 53...

  • Amyotrophe Lateralsklerose. Kollewe, K.; Dengler, R.; Petri, S. // Der Nervenarzt;Jun2008, Vol. 79 Issue 6, p653 

    Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease leading to death after 3 to 5 years. The glutamate antagonist Riluzole currently is the only drug with marginal therapeutic benefit but its effect on survival is modest, with an average increase of only 3-4 months. Therefore...

  • G-CSF Prevents the Progression of Structural Disintegration of White Matter Tracts in Amyotrophic Lateral Sclerosis: A Pilot Trial. Duning, Thomas; Schiffbauer, Hagen; Warnecke, Tobias; Mohammadi, Siawoosh; Floel, Agnes; Kolpatzik, Katja; Kugel, Harald; Schneider, Armin; Knecht, Stefan; Deppe, Michael; Schäbitz, Wolf Rüdigger // PLoS ONE;2011, Vol. 6 Issue 3, p1 

    Background: The hematopoietic protein Granulocyte-colony stimulating factor (G-CSF) has neuroprotective and - regenerative properties. The G-CSF receptor is expressed by motoneurons, and G-CSF protects cultured motoneuronal cells from apoptosis. It therefore appears as an attractive and feasible...

  • Prevalence of fatigue and depression in ALS patients and change over time. McElhiney, M. C.; Rabkin, J. G.; Gordon, P. H.; Goetz, R.; Mitsumoto, H. // Journal of Neurology, Neurosurgery & Psychiatry;Oct2009, Vol. 80 Issue 10, p25 

    Background: Amyotrophic lateral sclerosis (ALS) patients report both fatigue and depression. It is not clear how frequently each occurs, to what extent they occur together, how each relates to ALS disease status, or their stability over time. Objective: To assess frequency and persistence of...

  • Overcoming the barrier to ALS. Gaillard, P. J. // Laboratory News;May2013, Issue 5, p20 

    The article reports on the management of amyotrophic lateral sclerosis (ALS), a neurodegenerative condition for which there is currently no effective treatment. It states the significance of enhancing drug delivery to the brain of potential management of this disease. ALS is characterized by...

  • Amyotrophic Lateral Sclerosis As A Paraneoplastic Manifestation in the Neuroendocrine Tumor of Stomach: A Case Report. Mehrpour, Masoud; Mohebi, Nafiseh; Motamed, Mohammad Reza; Zamani, Farhad // Acta Medica Iranica;2013, Vol. 51 Issue 10, p724 

    Motor neuron diseases have been reported as a rare paraneoplastic syndrome (PNS) of a systemic neoplasm. We present a patient with amyotrophic lateral sclerosis (ALS) in association with neuroendocrine tumor (NET) of stomach, which is the first case of motor neuronopathy with underlying...

  • Mills' Syndrome -- A Clinical Variant -Case Report. EKMEKCİ, Hakan; OZTURK, Serefnur; DEMİR, Aysegul // Journal of Neurological Sciences;2013, Vol. 30 Issue 1, p210 

    The Mills' syndrome was first described by Mills in 1900, the syndrome included progressive, ascending or descending hemiplegia, with no significant sensory impairment. Opposing to be a variant of primary lateral sclerosis, this syndrome is accepted as degeneration of the corticospinal tract...

  • The Lon Protease Is Essential for Full Virulence in Pseudomonas aeruginosa. Breidenstein, Elena B. M.; Janot, Laure; Strehmel, Janine; Fernandez, Lucia; Taylor, Patrick K.; Kukavica-Ibrulj, Irena; Gellatly, Shaan L.; Levesque, Roger C.; Overhage, Joerg; Hancock, Robert E. W. // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Pseudomonas aeruginosa PAO1 lon mutants are supersusceptible to ciprofloxacin, and exhibit a defect in cell division and in virulence-related properties, such as swarming, twitching and biofilm formation, despite the fact that the Lon protease is not a traditional regulator. Here we set out to...

Share

Read the Article

Courtesy of MICHIGAN ELIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics